MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Park, Young Tae ^a   Jeong, Ju Yeon ^b   Lee, Mi Jung ^b   Kim, Kwang Il ^b   Kim, Tae Heon ^b   Kwon, Young Do ^b   Lee, Chan ^b   Kim, Ok Jun ^b   An, Hee Jung ^b  

^a Kosin University   (South Korea)

^b CHA University   (South Korea)

Author keywords

ALDH1; Cancer stem cell; Chemoresistance; microRNA; Ovarian cancer

Indexed keywords

ALDH 1 PROTEIN; MEMBRANE PROTEIN; MICRORNA; MIR 23B; MIR 27A; MIR 27B; MIR 346; MIR 424; MIR 503; TUMOR MARKER; UNCLASSIFIED DRUG;

ALDEFLUOR ASSAY; ARTICLE; ASSAY; CANCER STAGING; CELL POPULATION; CHEMORESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DISTANT METASTASIS; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; ONCOLOGICAL PARAMETERS; OVARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPHEROID FORMATION ASSAY; STEM CELL; UPREGULATION; VALIDATION PROCESS;

EID: 84875124469     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-18     Document Type: Article

References (35)

1. Cancer statistics, 2002. Jemal A, Thomas A, Murray T, Thun M, CA Cancer J Clin 2002 52 23 47 10.3322/canjclin.52.1.23 11814064 (Pubitemid 34110469)
2. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, J Clin Oncol 2003 21 3194 3200 10.1200/JCO.2003.02.153 12860964 (Pubitemid 46606249)
3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M, N Engl J Med 1996 334 1 6 10.1056/NEJM199601043340101 7494563 (Pubitemid 26012496)
4. Tumour stem cells and drug resistance. Dean M, Fojo T, Bates S, Nat Rev Cancer 2005 5 275 284 10.1038/nrc1590 15803154 (Pubitemid 40488633)
5. The increasing complexity of the cancer stem cell paradigm. Rosen JM, Jordan CT, Science 2009 324 1670 1673 10.1126/science.1171837 19556499
6. Stem cells and cancer: two faces of eve. Clarke MF, Fuller M, Cell 2006 124 1111 1115 10.1016/j.cell.2006.03.011 16564000
7. Stem cells, cancer, and cancer stem cells. Reya T, Morrison SJ, Clarke MF, Weissman IL, Nature 2001 414 105 111 10.1038/35102167 11689955 (Pubitemid 33041634)
8. MicroRNA signatures in human cancers. Calin GA, Croce CM, Nat Rev Cancer 2006 6 857 866 10.1038/nrc1997 17060945 (Pubitemid 44629897)
9. The functions of animal microRNAs. Ambros V, Nature 2004 431 350 355 10.1038/nature02871 15372042 (Pubitemid 39265675)
10. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438 (Pubitemid 38167318)
11. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Lewis BP, Burge CB, Bartel DP, Cell 2005 120 15 20 10.1016/j.cell.2004.12.035 15652477 (Pubitemid 40094598)
12. Oncomirs-microRNAs with a role in cancer. Esquela-Kerscher A, Slack FJ, Nat Rev Cancer 2006 6 259 269 16557279
13. Cancer stem cells and survival pathways. Hambardzumyan D, Becher OJ, Holland EC, Cell Cycle 2008 7 1371 1378 10.4161/cc.7.10.5954 18421251 (Pubitemid 351872575)
14. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Burgos-Ojeda D, Rueda BR, Buckanovich RJ, Cancer Lett 2012 322 1 7 10.1016/j.canlet.2012.02.002 22334034
15. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Cancer Res 2011 71 3991 4001 10.1158/0008-5472.CAN-10-3175 21498635
16. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP, Cancer Res 2008 68 4311 4320 10.1158/0008-5472.CAN-08-0364 18519691
17. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Hepatology 2009 50 472 480 10.1002/hep.22989 19585654
18. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Cell 2009 138 592 603 10.1016/j.cell.2009.07.011 19665978
19. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E, Cell 2007 131 1109 1123 10.1016/j.cell.2007.10.054 18083101 (Pubitemid 350235025)
20. MicroRNA profiling of a CD133+ spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line. Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, Kim YT, BMC Med Genomics 2012 5 18 10.1186/1755-8794-5-18 22643117
21. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S, Clin Cancer Res 2009 15 4234 4241 10.1158/1078-0432.CCR-08-1479 19509181
22. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL, J Cell Mol Med 2009 13 2236 2252 10.1111/j.1582-4934.2008.00455.x 18681906
23. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Mol Cancer Ther 2010 9 3186 3199 10.1158/1535-7163.MCT-10-0563 20889728
24. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J, Mod Pathol 2009 22 817 823 19329942
25. miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Liu W, Zabirnyk O, Wang H, Shiao YH, Nickerson ML, Khalil S, Anderson LM, Perantoni AO, Phang JM, Oncogene 2010 29 4914 4924 10.1038/onc.2010.237 20562915
26. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P, Portolani N, Giulini SM, De Petro G, Barlati S, FEBS J 2009 276 2966 2982 10.1111/j.1742-4658.2009.07014.x 19490101
27. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. Wang Y, Rathinam R, Walch A, Alahari SK, J Biol Chem 2009 284 23094 23106 10.1074/jbc.M109.012617 19546220
28. Expression and function of miR-27b in human glioma. Chen L, Li H, Han L, Zhang K, Wang G, Wang Y, Liu Y, Zheng Y, Jiang T, Pu P, Oncol Rep 2011 26 1617 1621 21922148
29. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Cancer Cell 2006 9 189 198 10.1016/j.ccr.2006.01.025 16530703 (Pubitemid 43357945)
30. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D, Genes Dev 2009 23 2152 2165 10.1101/gad.1820109 19759263
31. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes RM, Busund LT, PLoS One 2012 7 29671 10.1371/journal.pone.0029671 22295063
32. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, Xie X, Zhou C, Lu W, Oncogene 2013 32 976 987 10.1038/onc.2012.121 22469983
33. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z, Gynecol Oncol 2010 119 125 130 10.1016/j.ygyno.2010.06.004 20624637
34. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. Zhou J, Wang W, J Surg Oncol 2011 104 278 283 10.1002/jso.21941 21495032
35. CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation. Hayashi R, Goto Y, Ikeda R, Yokoyama KK, Yoshida K, J Biol Chem 2006 281 35633 35648 10.1074/jbc.M603800200 16984923 (Pubitemid 46041294)